Information Provided By: 
Fly News Breaks for March 15, 2018
IONS, ALNY
Mar 15, 2018 | 09:25 EDT
B. Riley FBR analyst Madhu Kumar says Ionis Pharmaceuticals' (IONS) inability to find an external partner for the commercial development of inotersen is a "material positive" for Alnylam Pharmaceuticals (ALNY) and its lead asset patisiran. He believes "middling efficacy, safety concerns, and IP risks" likely prevented an external partner from being interested in inotersen. The analyst keeps a Buy rating on Alnylam with a $200 price target.
News For ALNY;IONS From the Last 2 Days
ALNY
Apr 23, 2024 | 07:17 EDT
ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).
